~~<i id='120F1DB499'><strike id='120F1DB499'><tt id='120F1DB499'><pre id='120F1DB499'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

Wikipedia

author：focus 2025-09-07 21:55:30 - browse：23576

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Eli Lilly said Tuesday that it will purchase DICE Therapeutics, a small company developing an experimental pill to treat psoriasis, for $2.4 billion in cash.

The deal price of $48 per share represents a 42% premium to DICE’s closing price Friday.

“In combination with its novel technology and expertise in drug discovery, DICE’s talented workforce and passion for innovation will enhance our efforts to make life better for people living with devastating autoimmune diseases,” Patrik Jonsson, executive vice president, president of Lilly Immunology and Lilly USA, chief customer officer, said in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： STAT Virtual Event: JPM Recap, Live!

Wikipedia

hotspot

explore

focus

hotspot

Austin,Texashasbecomethegroundsforduelingpowerfulinterestsfightingoverhealthcareservicesforpoorpatie

WSS

Nonprofit, backed by Microsoft, to certify AI tools in health care

Medicare Advantage coverage denials need scrutiny, senators say

Why failed clinical trials don’t always spell doom for a new drug

Ascension's ugly legal battle over care for poor patients in Texas

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

South Korea throws huge K

leisure time

Wikipedia

Wikipedia

State Dept. review finds Biden bears some blame for Afghanistan failures

American woman, child freed after being kidnapped in Haiti last month

Medical records are filled with copy

Anavex keeps shifting the goalposts in its clinical trials

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

A biotech analyst on neuroscience, placebo effect, not over

In age of alternative facts, a scholarly course on calling out crap

Wegovy’s successful heart trial raises vital question about weight loss

Hepatitis C has a cure — but many Americans still lack access to it

What to know about Virgin Galactic's 1st mission taking paying customers to space

Wikipedia

Wegovy trial has doctors encouraged over new possibilities

For Cytokinetics, FDA rejection of heart drug would help, not hinder

In shift, Texas to cover initial consult for Afghan baby's gene therapy

JPM pitch from hospitals? Revenue streams outside of patient care

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Profiling embryos to choose those with higher IQs is almost a reality

hotspot

explore

focus

hotspot